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Abstract
Background: There is an ongoing debate whether combined antiretroviral treatment (cART) during pregnancy is an independent risk factor for prematurity in HIV-1 infected women. 
Objective: To examine 1) crude effects of different ART regimens on prematurity, 2) the association between length of cART and duration of pregnancy and 3) the role of possibly confounding risk factors for prematurity. 
Method: We analysed data from 1180 pregnancies prospectively collected by the Swiss Mother and Child HIV Cohort Study (MoCHiV) and the Swiss HIV Cohort Study (SHCS).
Results: Odds ratios for prematurity in women receiving mono/dual therapy and cART were 1.8 (95% CI: 0.85-3.6) and 2.5 (95% CI: 1.4-4.3) compared to women not receiving ART during pregnancy (p=0.004). In a subgroup of 365 pregnancies with comprehensive information on maternal clinical, demographic and life-style characteristics, there was no indication that maternal viral load, age, ethnicity, and history of injecting drug use affect prematurity rates associated to use of cART. Length of cART before delivery was also not associated with duration of pregnancy. 
Conclusion: Our study indicates that confounding by maternal risk factors or duration of cART exposure are not a likely explanation for the effects of ART on prematurity in HIV-1 infected women. 
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Introduction

There is an ongoing debate as to whether or not the use of combined antiretroviral treatment (cART) in pregnant women increases the risk of prematurity. An association between use of cART and preterm delivery was initially reported by the Swiss Mother and Child HIV Cohort Study (MoCHiV) in 1998 (​[1]​) and subsequently confirmed by the European Collaborative Study and the MoCHiV (​[2]​). Based on an analysis of nearly 4000 mother-child pairs, and controlling for maternal CD4+ cell count and injecting drug use, a two- to three-fold increase of prematurity for neonates of mothers treated with cART as compared to no ART or exclusive exposure to ZDV mono-prophylaxis during pregnancy was found. Furthermore, starting cART before pregnancy as compared to starting in the third trimester was associated with a two-fold increase of the prematurity risk. In contrast Tuomola et al (​[3]​) found similar rates of premature delivery of 16% and 17% among women who received antiretroviral therapy and those who did not. Combined ART was not associated with a higher prematurity rate or lower birth weights as compared to no ART or monotherapy during pregnancy. Their analysis was based on over 3000 mother-child-pairs enrolled between 1990 and 1998 in seven clinical studies in the USA. In addition to maternal CD4+ cell count, they were able to adjust premature birth rates in relation to cART exposure during pregnancy for the use of tobacco, alcohol and illicit drugs. 	

To explain the discrepancy between studies in the relationship between cART exposure during pregnancy and rate of premature birth, Tuomola et al (3) suggested confounding by other specific risk factors for prematurity in the ECS and MoCHiV analysis (2). The combined ECS and MoCHiV analysis was only controlled for maternal CD4+ cell count, intravenous drug use (IVDU) and maternal age, while information on other potential confounders was simply not available. For the Swiss pregnancy data included in the study this situation has changed following the full integration of MoCHiV into the adult Swiss HIV Cohort Study (SHCS). Following successful linkage of MoCHIV mother IDs to SHCS patient IDs additional maternal data, including comprehensive information on treatment history, demographic and life-style characteristics, became available for a substantial number of mothers. The updated information also allowed us to control for changes in potency of ART regimens prior and during pregnancy as well as alterations in clinical, demographic and life-style characteristics of mothers over the past 20 to 25 years. 

The main goal of the present study was to reassess the relationship between the ART regimen (no ART, mono/dual ART or cART) used prior and during pregnancy and the risk of premature birth. With respect to cART exposure, we particularly controlled for potential confounding by several maternal characteristics or risk factors during pregnancy, including lowest CD4 cell count during pregnancy, last HIV RNA load before delivery, age at conception, ethnicity, illicit drug use and smoking. We further investigated the association between the length of cART before delivery and the duration of pregnancy. 


Methods

Swiss Mother & Child HIV Cohort Study (MoCHiV) and Swiss HIV Cohort Study (SHCS)

MoCHiV is a merger of the original ‘Swiss Neonatal HIV‘ (​[4]​) und the ‘Swiss HIV and Pregnancy’ (​[5]​) Studies and contains prospectively collected data of HIV-infected mothers, their offspring and of HIV-infected children living in Switzerland. In 2003 MoCHiV has been fully integrated into the Swiss HIV Cohort Study (SHCS) (​[6]​). For women enrolled in both, the MoCHiV and the SHCS, precise information on antiretroviral therapy prior and during pregnancy as well as clinical conditions (e.g. CD4+ cell count, viral load, opportunistic infections) and possible (behavioural) risk factors for premature birth (such as smoking and illicit drug use) before and during pregnancy have become available. All data have been reported prospectively on structured worksheets and entered into the national database at the coordinating centre.
Informed consent was obtained from each woman participating in the SHCS and for each child’s parents or legal guardian before enrolment into MoCHiV, and local institutional ethics committee approval was obtained for both, the SHCS and MoCHiV.

Data selection and data analysis

Analyses were restricted to HIV‑1 positive women with a history of at least one pregnancy that was completed to live birth, excluding multiple (twin) pregnancies, which are commonly of shorter duration. Figure 1 shows a flow chart for further data selection. We excluded pregnancies that were terminated through elective caesarean section before 37 weeks of gestation (61 pregnancies to 30 mothers). The primary outcome ‘premature birth’ was defined as delivery before completion of the thirty- seventh week of pregnancy.

We investigated the effects of different ART regimens on prematurity in several ways.
Analysis 1 included all available data, i.e. 1180 pregnancies of 1040 mothers, and examined the association of prematurity and the type of ART exposure (no therapy, mono or dual therapy, and cART) without consideration of potential confounding maternal risk factors for prematurity, since such information has commonly been incomplete in the early years of MoCHiV (i.e. in women exclusively enrolled in MoCHiV). 
In analysis 2 we compared rates of premature birth in 418 pregnancies of 366 mothers exclusively on cART, who initiated treatment before or during pregnancy. Analysis 3 was further restricted to 334 pregnancies of 294 women under follow-up in the SHCS during pregnancy. For these women a detailed treatment history was available, which allowed us to investigate the relationship between the duration of cART, both prior to and during pregnancy, and prematurity or pregnancy duration.
The aim of analysis 4 was to control for a number of potential maternal confounders for prematurity and we therefore excluded 762 (of the initial 1180) pregnancies of 695 women who were not under follow-up in the SHCS during pregnancy. We further excluded 43 pregnancies of 41 mothers who did not receive ART during pregnancy and 10 pregnancies of 10 mothers without viral load measurement during pregnancy. The adjusted analysis was based on 365 pregnancies of 318 women.  

The main outcome is the risk of premature birth, which was analysed using logistic regression with a random effect on mother ID to account for dependence of multiple pregnancies in the same mother. Significance testing was performed using Wald tests. We thus investigated odds ratios for premature birth in relation to different types of ART that included three categories: no ART, mono or dual ART, and cART. We present results of univariable (analyses 1-3) and multivariable analyses (analysis 4), which included the following covariates: age of mothers at conception (16-24, 25-34 and 35-44 years); ethnicity (white, black, other/unknown); documented drug use prior or during pregnancy; documented smoking prior or during pregnancy; CD4+ cell count (lowest value during pregnancy) (0-100 cells/μL, 100-199 cells/μL, 200-349 cells/μL and 350 or more cells/μL); detectable viral load (last available determination before delivery) (≤ 400 copies/ml versus > 400 copies/ml). Plasma HIV-1 RNA copies were determined by ‘real-time’ PCR using the Amplicor HIV Monitor kit (Roche Molecular Diagnostics Kit, Roche Molecular Systems, Basel, Switzerland) and CD4+ T-cell counts were assessed using flow cytometry. 
All analysis were done using Stata software (StataCorp LP, Texas, USA), version 10.2.

Results

Patient characteristics

Overall 1180 pregnancies of 1040 mothers were included in the analysis; 762 were exclusively documented in the MoCHIV and 418 were included in both the MoCHiV and the SHCS. Maternal age at birth was documented for 1126 (95%) of pregnancies and median age was 29 years (IQR: 25-33 years). The total number of births was 463 (39%), 245 (21%) and 472 (40%) for the years before 1994 (period mainly without ART), 1994 to 1998 (period mainly with AZT prophylaxis according to PACTG-076​[7]​), and 1999 up to and including 2007 (period with available cART), respectively. Of the 829 (70%) women with indication of the most likely mode of transmission 579 (70%) were infected by sexual transmission and 219 (26%) by injecting drug use. Past or current tobacco smoking was indicated in 258 (22%) women (in the others either absent or not reported). A total number of 623 (53%) women did not receive antiretroviral therapy during pregnancy. Most of these pregnancies took place before 1995 when 99% (457 of 463 pregnancies) of women did not receive ART, decreasing to less than 5% (11 out of 244) from 2003 onwards. 

The most potent antiretroviral therapy during pregnancy was mono therapy in 94 (8%), dual therapy in 53 (4%), and triple (or triple-plus) therapy in 410 (35%) cases, respectively (table 1). In 73% of women zidovudine was part of any kind of treatment (409 out of 557) and cART was protease inhibitor based in 84% (385 out of 410). 

Progression in antiretroviral treatment and time trends in confounders

Figure 2 describes the use of ART and time trends in key factors influencing pregnancy outcomes over the years 1984 to 2007. Starting in the mid-90s there was a progressive increase in the percentage of women receiving ART during pregnancy. Over the last 10 years mono and dual prophylaxis during pregnancy were replaced by triple therapy, which reached coverage of 92% by the year 2007. There was a decline in the percentage of women with detectable viral load during pregnancy and an increase in the median CD4+ cell count during pregnancy in parallel with increasing effectiveness of ART. In addition the percentage of women with a history of injecting drug use (IDU) as well as the proportion of women that reported smoking during pregnancy declined with calendar year, whereas maternal age and the proportion of black women increased over time.

ART during pregnancy

Table 1 shows pregnancy outcomes in relation to type of ART exposure during pregnancy (Analysis 1). The median gestational age was 39 weeks in women who did not receive ART as compared to 38 weeks in those receiving mono or dual therapy, respectively receiving cART. The cumulative distribution of gestational age by type of ART exposure is shown in Figure 3 and differed between groups (log-rank chi-square=227.82, p<0.0001). Accordingly, median birth weight of the children was about 170 g higher in women not receiving ART as compared to those receiving ART, while there was no difference in child birth weight between women who received mono or dual ART vs. cART (Table 1). Premature birth rates increased from 15.8% before 1994 to 28% after 1998, and accounted to 15%, 20% and 24% for woman receiving no therapy, mono or dual therapy and cART, respectively. The odds ratios for prematurity in women receiving mono or dual therapy and cART as compared to women who did not receive ART during pregnancy were 1.8 (95% CI: 0.85-3.6) and 2.5 (95% CI: 1.4-4.3) (LR test, p=0.0025; Table 1). The  numbers of extreme premature births < 32 weeks of gestation were 9 (1.4%), 4 (2.6%), and 11 (2.5%) in the no treatment, mono/dual and cART treatment groups, respectively.

Start of HAART:  prior vs. during pregnancy

A total of 418 women on cART included in both, the SHCS and MoCHiV (Analysis 2) started treatment before (n=214) or during (n=204) pregnancy. The median duration of gestation was 37.5 weeks and not related to the timing of the start of cART. Prematurity rates were 23% and 26% in women starting cART before and during pregnancy, respectively.  The corresponding odds ratio was 1.21 (95% CI: 0.54-2.72) and not statistically significant. There was also no relationship between the total duration on cART before and during pregnancy and the risk of premature birth (random effects linear regression, p=0.53) or the duration of gestation (data not shown) (Analysis 3). Taking the risk of prematurity starting cART in the third trimester of pregnancy as reference, the odds ratio for starting cART in the first and second trimester or before pregnancy were 1.56 (95% CI 0.25-9.8) and 1.72 (95% CI 0.33-8.96), respectively.

Maternal risk factors and prematurity 

We finally investigated a number of maternal risk factors for premature birth in women with complete data (Analysis 4) that were registered in the SHCS. The unadjusted and adjusted odds ratios for the risk of prematurity comparing women receiving cART with women receiving mono or dual therapy during pregnancy were very similar, namely 5.35 (95% CI 0.33-87.5) and 3.87 (95% CI 0.23-63.65), indicating little confounding by other maternal risk factors. There was also a weak association of low maternal CD4+ cell count and cigarette smoking with an increased risk of prematurity, both in the univariable and the multivariable analysis. However, confidence intervals to the estimates were wide for both, cART and CD4+ cell count, and also for nicotine use. Maternal age, ethnicity, history of drug use and viral load were not associated with the risk of prematurity (Table 2).


Discussion

There is controversy as to whether exposure to cART in HIV-1 infected pregnant women increases the rate of premature birth. It has specifically been argued that heterogeneity in outcomes of previous studies (1,2,3,​[8]​) may have been caused by uncontrolled confounding from maternal risk factors in studies indicating elevated risk of prematurity, which includes the initial study based on data from the Swiss MoCHIV cohort (1). Here we reanalyzed the updated Swiss data, which provided more complete and precise information on potential risk factors for prematurity, exact duration and composition of antiretroviral treatment, and maternal lifestyle characteristics following the integration of MoCHIV in the SHCS. 

In agreement with our earlier combined study with the ECS (2), we found a positive association between intensity of ART regimen (changing no ART, to any ART regimen, to cART) and the risk of premature birth in a crude analysis of all available pregnancies (Analysis 1). Prematurity rates increased with calendar year in HIV-1 infected pregnant women, as shown in other studies (​[9]​). This trend was in accordance with the increasing intensity of ART regimens with calendar year, but not with changes in key maternal risk factors for prematurity. In line with the intensified ART, pregnant women showed an increase in the median CD4 count and decline in the proportion with detectable viral load, while the prevalence of tobacco use and injecting drug use declined. Further analyses (Analyses 2 and 3) that included women exclusively on cART and with precise information about the time point of initiation of their treatment indicated higher prematurity rates in children whose mothers started cART before pregnancy as compared to mothers starting in the third trimester, similar to our previous ECS/MoCHiV study (2). However, the risk of prematurity was not different between mothers starting cART before or during pregnancy, and there was also no association between the total duration of cART before delivery and the duration of pregnancy. 

Due to incompleteness of data in the early MoCHiV data base, our crude time trend analysis of potentially confounding risk factors for prematurity in all pregnancies (Figure 2) has to be interpreted with caution. For instance, available information on maternal smoking was imperfect, because no indication of tobacco use may also signify that no information about smoking behaviour was available. In order to overcome such problems we performed a multivariate analysis in a subgroup of women for which precise information was available (Analysis 4). This subgroup analysis showed similar unadjusted and adjusted odds ratios for maternal cART and CD4+ cells count, indicating little confounding by other maternal risk factors. Odds ratios for smoking were also substantial. Results of this analysis did not reach statistical significance most likely due to the limited sample size available for this analysis. Nevertheless, these findings correspond to the results of other evaluations (time trend analysis and analysis 1) in the present study, rendering incidental results of analysis 4 quite unlikely. We were unable to adjust for the effect of drinking habits as this information was recorded only recently in the SHCS database. Other socioeconomic and obstetric factors identified and summarized in literature (​[10]​) were also not available or outside of the focus of our analysis. Given the high inclusion rates into the SHCS (6), the time trend analysis as well as our multivariate analysis (Analysis 4) are representative for HIV-1 infected pregnant women living in Switzerland.  

In concordance with our data, the initial confirmation of an increased prematurity rate associated with ART during pregnancy by Thorne et al (2) has further and consistently been supported by additional analyses reported by the ECS. In their most recent analysis of 2’326 mother-child pairs, Hanking et al (​[11]​) reported an overall prematurity rate of 17% and a significant association of antenatal ART exposure with prematurity in univariable and multivariable analyses adjusting for maternal CD4+ count, injecting drug use and maternal age. Women receiving a PI-sparing cART regimen were nearly three times more likely to deliver prematurely than those receiving no therapy, and those with a PI-based cART regimen were four times more likely to deliver prematurely. Overall, 2% (40/2326) of infants had a gestational age of less than 32 weeks, but this proportion was 4% (8/188) in infants exposed to combination therapy with a PI (p = .005). Our data suggest an increased rate of extreme prematurity (< 32 weeks) in case of exposure to any kind of ART. In a subsequent analysis, Thorne et al (9) reported a significant increase of the prematurity rate from 16.4% in 1985–1989 to 24.9% in 2000–2004, similar to our findings. 

Increased prematurity rates associated with maternal cART were also reported in studies based on data from Germany/Austria (​[12]​) , UK/Ireland (​[13]​) and Italy (​[14]​). In a large US study, however, including more than 11,000 infants, evidence was found, that both, the proportion of LBW infants and preterm birth rates declined over time, while use of any ART regimen increased substantially during the same time period (​[15]​). This study found an association between preterm birth and both, no ART and cART with a PI. Of note maternal CD4+ cell counts and viral load data were not available in this analysis. Kourtis et al (​[16]​) performed a large meta analysis including thirteen prospective and one retrospective studies from Europe and the USA. They concluded that the use of combination regimens before or early in pregnancy slightly increases the risk of prematurity, but also that antiretroviral therapy during pregnancy was not associated with an overall increased risk of premature delivery (OR 1.01, 95%CI 0.76-1.34). PI-containing regimens were associated with a slightly increased risk of prematurity, whereas the use of monotherapy was associated with a slightly decreased risk. Of note, in Switzerland, virtually all pregnant women who receive cART during pregnancy were prescribed PI-containing regimens, which could at least in part explain the differences with US data, where this proportion might be lower (​[17]​). Recently, Fiore et al (​[18]​) reported, that ART increased interleukin (IL)-2 and decreased IL-10 production by peripheral blood mononuclear cells, and that an increase in IL-2 was independently associated with an increase in the risk of prematurity. They speculated that this antiretroviral-associated modulation of the immune response could be one explanation for the observed prematurity increase in women with ART.

In conclusion our study lends support to the view that treatment of pregnant women with cART for their own health or for vertical transmission prophylaxis is associated with increased rates of premature birth. We were able to adjust for a number of confounding factors for prematurity in a subgroup of well documented women. Even though the risk for prematurity might be more pronounced in women with the longest as compared to those with the shortest duration of PI-based treatment, we were not able to demonstrate a difference in prematurity rates between groups of women who started cART before or during pregnancy nor a direct correlation between the length of cART until delivery and the duration of pregnancy. 
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Figure Legends

Figure 1: Flow chart for data selection and creation of data sets used in analyses. # $ identical numbers have arisen by chance, based on a different selection of pregnancies (women).

Figure 2:  Progression of types of antiretroviral therapy (ART), clinical characteristics (i.e., CD4 cell count and viral load during pregnancy) and key factors influencing preterm delivery (i.e. maternal age, drug use and smoking) with calendar year in the MoCHIV/SHCS cohort from 1985 to 2007.

Figure 3: Cumulative distribution of gestation age by type of ART exposure.
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